Hovione launches first clinical trial, more to come

By Melissa Fassbender contact

- Last updated on GMT

Hovione produces active pharmaceutical ingredients (APIs) and conducts drug product intermediates development and manufacture. (Image: iStock/Delpixart)
Hovione produces active pharmaceutical ingredients (APIs) and conducts drug product intermediates development and manufacture. (Image: iStock/Delpixart)

Related tags: Pharmacology

Hovione has launched its first clinical trial and has already set sights on a second as the CDMO hopes to establish licensing partnership with pharma, says VP.

The contract development and manufacturing organization (CDMO) has four FDA inspected sites in the US, China, Ireland, and Portugal and development laboratories in Lisbon, Portugal, and the US.

The first-in-human study of HY02, a proprietary minocycline sterile ointment to treat a subset of ocular surface inflammation, is a double-blinded, randomized trial and will enroll approximately 36 subjects over the next few months. The company expects topline results by the end of the year. 

Product Development and Licensing is a new business area for Hovione with the mission of developing Hovione’s medicines​,” Carla Vozone, VP, product development and licensing, told Outsourcing-Pharma.com.

The difference from our core and established business is that in this new area we identify certain target diseases in the areas of ophthalmology, dermatology and inhalation in which Hovione’s know-how and technology platforms can contribute to develop an innovative medicine to the patient​,” she said.

The company uses known molecules and repurpose them in new routes of administration or new indications, Vozone explained.

The CDMO plans to develop its products up to proof-of-concept and then out-license to pharmaceutical companies interested in further development, registration, and commercialization.

Vozone said the company is planning to launch another clinical trial during 2017.

Over the next 5 years we hope to establish licensing partnerships with pharmaceutical companies and progress further the clinical development and NDA filing​,” she added.

Related news

Show more

Related products

show more

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Innovations in OSD

Innovations in OSD

Recorded the 06-Oct-2020 | Webinar

This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars